VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Rating of “Reduce” by Analysts

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has been given a consensus rating of “Reduce” by the five analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $0.95.

VTGN has been the topic of several analyst reports. Wall Street Zen cut VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Finally, William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th.

VistaGen Therapeutics Price Performance

NASDAQ:VTGN traded down $0.04 during trading hours on Friday, hitting $0.56. The company had a trading volume of 287,068 shares, compared to its average volume of 945,106. The stock has a 50-day moving average price of $0.59 and a 200 day moving average price of $2.30. The company has a market capitalization of $22.31 million, a PE ratio of -0.30 and a beta of 0.29. VistaGen Therapeutics has a 52 week low of $0.43 and a 52 week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. Analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Investors Weigh In On VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC purchased a new stake in VistaGen Therapeutics during the 1st quarter valued at $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in VistaGen Therapeutics during the third quarter valued at $39,000. Millennium Management LLC purchased a new stake in VistaGen Therapeutics during the third quarter valued at $73,000. Bank of America Corp DE lifted its holdings in VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in VistaGen Therapeutics in the third quarter worth about $112,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.